RINVOQ is an oral selective and reversible JAK inhibitor indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.1
EULAR European Congress of Rheumatology 2022
June 1-4, 2022 | Copenhagen, Denmark
Join us in Copenhagen for the 75th anniversary of EULAR.
[Affiliates to insert congresses and meetings as approved by local guidance.]
TITLE OF EVENT TBD
Date | Location
Description
[Affiliates to insert congresses and meetings as approved by local guidance.]
Starting patients on RINVOQ: Helpful information
This convenient guide helps educate you on starting patients on RINVOQ, with information on dosing plus screening, monitoring, and safety recommendations.
Resource item
number 2
Resource item number 2 description tbd lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna.
Resource item
number 3
Resource item 3 description tbd lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna.
Support for your patients, every step of the way
Personalized support services, tailored to your patients' needs
We offer a range of services for your patients to help support them.
Find out more about patient support services.
You may also be interested in
I want to receive more information
via a product specialist.
I have a question for
Medical Information.
- RINVOQ [Summary of Product Characteristics]. AbbVie Deutschland GmbH & Co. KG.